Elucidation of the Role of SMAD4 in Epithelial–Mesenchymal Plasticity: Does It Help to Better Understand the Consequences of DPC4 Inactivation in the Malignant Progression of Pancreatic Ductal Adenocarcinoma?
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer-related mortality worldwide, with a 5-year-survival rate below 10% that is the lowest of all cancer types [...]
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DPC4 gene frequently experiences inactivation in PDAC, leading to enhanced metastasis and worse prognosis.
“The DPC4 gene, encoding SMAD4, frequently experiences inactivation in PDAC, leading to enhanced metastasis and worse prognosis.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [118]
The paper states that DPC4 encodes SMAD4 and is inactivated in 50–55% of patients with PDAC. It links DPC4 loss to enhanced metastasis and worse prognosis, but describes that link as apparent rather than established causation; it also reports that several large studies found no prognostic impact. These passages are from the paper’s main text; page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredPatients with DPC4-expressed cancers exhibit longer survival.
“Patients with DPC4-expressed cancers exhibit longer survival, emphasizing the significance of SMAD4 in treatment outcomes.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [118]
The discussion of survival and therapy resistance (page not provided) reports worse disease-free survival with DPC4 inactivation in a specific subset of patients, which lends limited support to the claimed association. But it also says several large retrospective studies found no effect on overall or disease-free survival. The paper discusses pancreatic ductal adenocarcinoma, not cancers generally, and does not establish that patients with DPC4-expressing tumors consistently live longer. (LLM, conf=0.86)
Experimental — accuracy not yet measuredSMAD4 loss is associated with distant metastases.
“Notably, SMAD4 loss is associated with distant metastases, highlighting its role in disease progression patterns [72,73,74,75,76,118].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226 · see citing works
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works
Identification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Keymeulen, A. V., Brown, D. V., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,488 · see citing works
EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., Yamazoe, T., Black, T. A., Sahmoud, A., Furth, E. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.027 · Cited by 708 · see citing works
TGF-β Tumor Suppression through a Lethal EMT
David, C. J., Huang, Y.-H., Chen, M., Su, J., Zou, Y., Bardeesy, N. M., Iacobuzio–Donahue, C. A., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.01.009 · Cited by 597 · see citing works
Ramachandran, A., Vizán, P., Das, D., Chakravarty, P., Vogt, J., Rogers, K. W., Müller, P., Hinck, A. P., Sapkota, G. P., & Hill, C. S. (2018) · eLife · doi:10.7554/elife.31756 · Cited by 204 · see citing works
Kohler, I., Bronsert, P., Timme, S., Werner, M., Brabletz, T., Hopt, U. T., Schilling, O., Bausch, D., Keck, T., & Wellner, U. F. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12752 · Cited by 93 · see citing works
Self-citationHuang, W., Navarro-Serer, B., Jeong, Y. J., Chianchiano, P. E., Xia, L., Luchini, C., Veronese, N., Dowiak, C., Ng, T., Trujillo, M. A. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1523 · Cited by 86 · see citing works
Na, Y., Seok, S. H., Kim, D., Han, J., Kim, T., Jung, H. J., Lee, B., & Park, J. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01301.x · Cited by 75 · see citing works
Thakur, A. K., Nigri, J., Lac, S., Leca, J., Bressy, C., Berthézène, P., Bartholin, L., Chan, P., Calvo, E. L., Iovanna, J., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.18 · Cited by 47 · see citing works
Racu, M.-L., Lebrun, L., Schiavo, A. A., Campenhout, C. V., Clercq, S. D., Absil, L., Minguijón, E., Maris, C., Decaestecker, C., Salmon, I. J., et al. (2022) · Cancers · doi:10.3390/cancers14040973 · Cited by 29 · see citing works
Ungefroren, H., Thürling, I., Färber, B., Kowalke, T., Fischer, T., de Assis, L. V. M., Braun, R., Castven, D., Oster, H., Konukiewitz, B., et al. (2022) · Cancers · doi:10.3390/cancers14092057 · Cited by 25 · see citing works
Self-citationCanonical BMP Signaling Executes Epithelial-Mesenchymal Transition Downstream of SNAIL1
Frey, P., Devisme, A., Schrempp, M., Andrieux, G., Boerries, M., & Hecht, A. (2020) · Cancers · doi:10.3390/cancers12041019 · Cited by 22 · see citing works
Ungefroren, H., Braun, R., Lapshyna, O., Konukiewitz, B., Wellner, U. F., Lehnert, H., & Marquardt, J. U. (2022) · Biomedicines · doi:10.3390/biomedicines10102640 · Cited by 7 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110 · see citing works
Yao, H.-J., Luo, L., Li, R. Q., Zhao, Y., Zhang, L., Pešić, M., Cai, L., & Li, L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189220 · Cited by 19 · see citing works
Lin, H.-J. L., Liu, Y., Caroland, K. P., & Lin, J. (2023) · Cancers · doi:10.3390/cancers15133507 · Cited by 19 · see citing works
- Authors
- Ungefroren, H., Konukiewitz, B., Braun, R., Wellner, U. F., Keck, T., & Marquardt, J.-U.
- Affiliations
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Ungefroren, Hendrik
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-01-18
- Volume
- 15
- Issue
- 3
- Pages
- 581
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9913373
- OpenAlex
- W4317206957
- Cited by
- 3
- References
- 14
- Citations by year
- 2024: 2 · 2023: 1
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- SMAD4, epithelial-mesenchymal plasticity, pancreatic ductal adenocarcinoma, tumor progression, tumor suppressor inactivation, metastasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
